Search
Read all the latest Discovery Centre news and events.
Help shape how hospitals care for children and families by joining one of our Consumer Advisory Groups
News & Events
Discovery Centre is openingWe are delighted to announce that on Monday 6th July 2020 at 9am the Discovery Centre will reopen it’s doors to the public!
Here we recognise donors who have made cumulative gifts of $10,000 and above to contribute to children's health research at The Kids Research Institute Australia.
Derbarl Yerrigan Health Service (DYHS) has developed a holistic paediatric service unit anchored in primary health care and underpinned by care coordination provided by an experienced nurse and multi-disciplinary team.
The Wal-yan Respiratory Research Centre is made up of multi-disciplinary teams that are committed to improving the lives of children and their families living with respiratory disease.
Research
Skin InfectionsOur skin, the body’s largest organ, protects us and maintains overall health. Untreated recurring skin infections like impetigo and scabies severely impact children. The Kids is at the forefront of combatting skin infections, particularly within remote Aboriginal communities experiencing some of the world’s highest rates.
Research
Nirsevimab immunisation of infants and respiratory syncytial virus (RSV)-associated hospitalisations, Western Australia, 2024: a population-based analysisChristopher Peter Hannah Blyth Richmond Moore MBBS (Hons) DCH FRACP FRCPA PhD MBBS MRCP(UK) FRACP OAM BSc (Hons) GradDipClinEpi PhD Centre Head,
Research
Rett Syndrome Behaviour Questionnaire: Variability of Scores and Related FactorsRett syndrome (RTT) is a severe neurodevelopmental disorder affecting predominantly females and associated with variants in the MECP2 gene. Recent success in clinical trials have resulted in an expanded use of the Rett Syndrome Behaviour Questionnaire (RSBQ) for clinical and research purposes.
Research
Preclinical Assessment of Dactinomycin in KMT2A-Rearranged Infant Acute Lymphoblastic LeukemiaInfants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have high rates of relapse and poor survival compared with children. Few new therapies have been identified over the past twenty years. The aim of this study was to identify existing anti-cancer agents that have the potential to be repurposed for the treatment of infant ALL.